| Botson, John |
FORWARD OL, NCT04762498: A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout |
|
|
| Completed | 4 | 50 | US | Pegloticase, Methotrexate (MTX) | Amgen | Uncontrolled Gout, Chronic Gout | 05/23 | 12/23 | | |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
NCT04987294: Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease |
|
|
| Terminated | 2a | 19 | US | ALLN-346, Engineered urate oxidase, Placebo, Matching placebo capsule | Allena Pharmaceuticals | Hyperuricemia, Gout, Chronic Kidney Diseases | 09/22 | 09/22 | | |
| Sharobeem, Andrew |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab | Novartis Pharmaceuticals | Polymyalgia Rheumatica | 09/25 | 02/26 | | |
